Award Number: DAMD17-98-1-8313

TITLE: Structural and Signaling Requirements for C-erbB2 Antiapoptosis in Breast Cancer

PRINCIPAL INVESTIGATOR: Tong Jing, B.M.

CONTRACTING ORGANIZATION: The University of Texas M.D. Anderson Cancer Center
Houston, Texas 77030

REPORT DATE: June 2000

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
**Title and Subtitle**

Structural and Signaling Requirements for C-erbB2 Antiapoptosis in Breast Cancer

**Author(s)**

Tong Jing, B.M.

**Performing Organization Name(s) and Address(es)**

The University of Texas M.D. Anderson Cancer Center
Houston, Texas 77030

**Sponsoring / Monitoring Agency Name(s) and Address(es)**

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

**Abstract (Maximum 200 Words)**

The c-erbB2 (or HER-2, neu) gene encodes a 185-kDa transmembrane glycoprotein (p185), which belongs to the EGF-r family. The c-erbB2 gene was found to be amplified and/or overexpressed in approximately 30% of human breast carcinomas. Our previous studies demonstrated that c-erbB2 overexpression can enhance metastatic potential and confer increased chemoresistance to breast cancer cells, thereby leading to poor clinical outcome in breast cancer patients. Our recent studies demonstrated that overexpression of the c-erbB2 gene can protect human breast cancer cells from apoptosis induced by the chemotherapeutic agent Taxol. One of the mechanisms is overexpression of c-erbB2 can upregulate p21Cip1, which inhibits taxol-mediated p34Cdc2 activation, delays cell entrance to G2/M phase, and thereby inhibits taxol-induced apoptosis. This new finding provided an explanation on c-erbB2 mediated chemoresistance of breast cancer cells and also explored the importance of p21Cip1 in G2/M phase transition. Since we only use the 435 and its c-erbB2 transfectants in this study, we would like to further confirm this in other c-erbB2 overexpression breast cancer cell lines with different genetic background. Then we will find out whether other p34Cdc2 regulators contribute to taxol resistance.

**Subject Terms**

Breast Cancer, Predoctoral, tyrosine kinase, erbB2, apoptosis
Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

N/A In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature 6/12/2000

Date
Table of Contents

Cover.................................................................1
SF 298...............................................................2
Foreword..........................................................3
Table of Contents................................................4
Introduction......................................................5
Body.................................................................5
Key Research Accomplishments..............................
Reportable Outcomes...........................................
Conclusions......................................................7
References.........................................................7
Appendices.......................................................8
Progression Reports for 1999-2000

A. Introduction

The c-erbB2 (or HER-2, neu) gene encodes a 185-kDa transmembrane glycoprotein (p185), which belongs to the EGF-r family. The c-erbB2 gene was found to be amplified and/or overexpressed in approximately 30% of human breast carcinomas. Our previous studies demonstrated that c-erbB2 overexpression can enhance metastatic potential and confer increased chemoresistance to breast cancer cells, thereby leading to poor clinical outcome in breast cancer patients. Our recent studies demonstrated that overexpression of the c-erbB2 gene can protect human breast cancer cells from apoptosis induced by the chemotherapeutic agent Taxol. One of the mechanisms is overexpression of c-erbB2 can upregulate p21\textsuperscript{Cipl}, which inhibits taxol-mediated p34\textsuperscript{Cdc2} activation, delays cell entrance to G2/M phase, and thereby inhibits taxol-induced apoptosis. This new finding provided an explanation on c-erbB2 mediated chemoresistance of breast cancer cells and also explored the importance of p21\textsuperscript{Cipl} in G2/M phase transition. Since we only use the 435 and its c-erbB2 transfectants in this study, we would like to further confirm this in other c-erbB2 overexpression breast cancer cell lines with different genetic background. Then we will find out whether other p34\textsuperscript{Cdc2} regulators contribute to taxol resistance.

B. Specific Aims

The specific Aims 1 and 2 have been modified. Since we found that the activity of p34\textsuperscript{Cdc2} is important of taxol-induced apoptosis. In our early finding that p21\textsuperscript{Cipl}
play an important role in 435.eB transfectants to inhibit the activity of p34$^{Cdc2}$. We plan to study other c-erbB2 overexpression breast cancer cell lines to see whether this is a general phenomenal.

**Aim 1. Identify p34$^{Cdc2}$ regulators involved in Taxol resistance in breast cancer cell lines.**

**Aim 2. Investigate these p34$^{Cdc2}$ regulators are direct involved in Taxol resistance in breast cancer cell lines.**

**C. Study Results and Significance**

**Aim 1. Identify p34$^{Cdc2}$ regulators involved in Taxol resistance in breast cancer cell lines.**

To determine whether the activity of p34$^{Cdc2}$ is important in other breast cancer cell lines, we use two taxol sensitive breast cancer cell lines MDA-MB-435, MDA-MB-231 and two taxol resistant cell lines BT 474, MDA-MB-361 (Appendices Fig.1), to compare their p34$^{Cdc2}$ activity. Since phosphorylation of tyrosine 15 residue is an indication of inhibition of p34$^{Cdc2}$ activity, I used immunoblotting with phospho-tyr-15 specific antibody to determine the activity of p34$^{Cdc2}$ in these four cell lines (Appendices Fig.2). The phosphorylation of tyrosine 15 is higher in taxol resistant cell lines compared with taxol sensitive cell lines. Since Wee1 and Cdc25C are two important regulators to regulate the phosphorylation status on p34$^{Cdc2}$ tyrosine 15 residue, I screened these two factors by using immunoblotting. Interestingly, Wee1 expression level is higher in BT474 and 361 cell lines (Fig.3.). I also screened other p34$^{Cdc2}$ regulators p21$^{Cip1}$ and cyclin B1(1). As expected, p21$^{Cip1}$ expression level is higher in BT 474 and 361 cell lines (Fig.4.) whereas
cyclin B1 expression level is much lower in these two cell lines (1). From above data, multiple regulators are involved in regulating the taxol sensitivity. Currently, aim 1 already been finished, I will start the aim 2 study.

D. Plans

**Aim 1. Identify p34^{Cdc2} regulators involved in Taxol resistance in breast cancer cell lines.**

Finished.

**Aim 2. Investigate these p34^{Cdc2} regulators are direct involved in Taxol resistance in breast cancer cell lines.**

I will design or construct anti-sense p21 oligonucleotide, anti-sense wee1 plasmid and cyclin B1 plasmid, transfetc each one of them into the taxol resistant cell lines BT474 and 361. Then to investigate whether bring down or bring up one of these factors can resensitize the breast cancer cell to taxol induced apoptosis.

E. Conclusions

With the data we already had, overexpression of c-erbB2 can confer the taxol induced apoptosis by upregulation of p21^{Cip1}, which in turn inhibits the taxol mediated activation of p34^{Cdc2}. But in other breast cancer cell lines, other p34^{Cdc2} regulators like Weel and cyclin B1 also play a role in p34^{Cdc2} inhibition. These leading us to find out that p34^{Cdc2} may be an important target for taxol resistance.

F. Reference

**Appendices**

**FIGURE 1.** DNA ladder assay of breast cancer cell lines sensitivity to taxol induced apoptosis

<table>
<thead>
<tr>
<th>Taxol (μM)</th>
<th>M</th>
<th>MDA-MB-435</th>
<th>MDA-MB-231</th>
<th>BT-474</th>
<th>MDA-MB-361</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.02</td>
<td>0</td>
<td>0.02</td>
<td>0.02</td>
<td>15</td>
</tr>
<tr>
<td>0</td>
<td>0.02</td>
<td></td>
<td></td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>0</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0.02</td>
</tr>
</tbody>
</table>

**FIGURE 2.** Western Blotting of phosphorylation of Cdc2 in different breast cancer cell lines

<table>
<thead>
<tr>
<th></th>
<th>435</th>
<th>231</th>
<th>474</th>
<th>361</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0</td>
<td>8</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>8</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>8</td>
<td>20</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

-cdc2(Y15)

-cdc2(total)

-actin
Figure 3. Western blotting of Wee1 and Cdc25C expression level in breast cancer cell lines

<table>
<thead>
<tr>
<th></th>
<th>MDA-MB-435</th>
<th>MDA-MB-231</th>
<th>BT-474</th>
<th>MDA-MB-361</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taxol(hr)</td>
<td>0 8 20</td>
<td>0 8 20</td>
<td>0 8 20</td>
<td>0 8 20</td>
</tr>
<tr>
<td>Wee1-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cdc-25C-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-actin-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 4. Western blotting of p21 expression level in breast cancer cell lines

<table>
<thead>
<tr>
<th></th>
<th>MDA-MB-435</th>
<th>MDA-MB-231</th>
<th>BT-474</th>
<th>MDA-MB-361</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time(hr)</td>
<td>0 8 20</td>
<td>0 8 20</td>
<td>0 8 20</td>
<td>0 8 20</td>
</tr>
<tr>
<td>p21-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CyclinB1-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-actin-</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>